Veracyte completed its Acquisition of Convergent for $150 million in cash on September 14, 2026. The transaction matters because it brings Convergent’s UroAmp and proprietary urine tumor DNA technology into Veracyte’s roadmap, while securityholders may receive up to $30 million tied to specified milestones.

Key Highlights

  • Convergent became a wholly owned Veracyte Subsidiary after the Merger took effect on September 14, 2026.
  • Up to $30 million in additional cash consideration depends on specified UroAmp publication and reimbursement milestones.
  • Veracyte entered into the merger agreement on September 10, 2026, and paid Convergent securityholders aggregate cash consideration of $150 million, subject to customary purchase price adjustments.

Veracyte, Inc. (NASDAQ: VCYT) completed its acquisition of Convergent Genomics Inc. for $150 million in aggregate cash consideration, subject to customary purchase price adjustments. The transaction took effect on September 14, 2026, with Convergent continuing as a Wholly Owned Subsidiary of Veracyte.

$150M Convergent Deal Closes

Veracyte entered into the merger agreement on September 10, 2026, with Compass Merger Sub Inc. and Convergent. Under the transaction structure, Merger Sub merged into Convergent, and its separate corporate existence ended while Convergent remained as the surviving corporation.

UroAmp Milestones Set Terms

The agreement allows Veracyte to pay Convergent securityholders up to $30 million in additional cash consideration. The potential payments depend on specified milestones connected with UroAmp publications and reimbursement efforts. The agreement also contains representations, warranties, covenants and agreements from Veracyte and Convergent, along with post-closing indemnification provisions. Veracyte may pay additional cash consideration tied to specified UroAmp publications and reimbursement efforts.